Thierry Fumeaux

Tell us more about your current roles with kinarus and acthera. I am the newly appointed CEO of Acthera Therapeutics, an early-stage biotech company, developing a unique type of mechanosensitive liposomes, enabling the controlled and targeted delivery of therapeutic molecules, when and where they can exert their pharmacologic